Skip to main content
x

Recent articles

Bristol goes pivotal with SystImmune-partnered conjugate

The first global pivotal trial will be in first-line triple-negative breast cancer.

RemeGen cools on DR5

A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.

Mural hits a wall

The company scraps nemvaleukin after the latest failure, of Artistry-6.

J&J broadens its bladder cancer push

TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.

Telix sees more backing for LAT1

TLX101 follows Ipax-1 with an apparent success in an academic trial.

Xencor could face second challenge from former partner

J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.